Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00115011 · ClinicalTrials.gov registry record · Phase 4
Escitalopram for the Treatment of Self-Injurious Skin Picking
A Phase 4 study of Impulse Control Disorders, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT00115011 is a Phase 4 study of Impulse Control Disorders that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.
The verdict
NCT00115011, a Phase 4 study of Impulse Control Disorders, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking.
Conditions Studied
Interventions
- DRUG Escitalopram
Study Locations (1)
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-09 |
| Est. Completion | 2005-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00115011
The ClinicalTrials.gov registry entry for NCT00115011 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Impulse Control Disorders appearing as the primary indexed condition, and to 1 intervention - of which Escitalopram is the first listed.
NCT00115011 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00115011 about?
NCT00115011 is a clinical study titled "Escitalopram for the Treatment of Self-Injurious Skin Picking". The purpose of this study is to determine the effectiveness of escitalopram in treating self-injurious skin picking.
What is the current status of trial NCT00115011?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2002-09. Estimated completion is 2005-11.
What conditions does trial NCT00115011 study?
This clinical trial studies the following conditions: Impulse Control Disorders.
What interventions are being tested in trial NCT00115011?
The interventions under investigation include: Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00115011?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00115011 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Impulse Control Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.